The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease

被引：0
|
作者：
Lars Holger Ehlers
Mark Lamotte
Sofia Monteiro
Susanne Sandgaard
Pia Holmgaard
Evan C. Frary
Niels Ejskjaer
机构：
[1] Aalborg University,Department of Clinical Medicine
[2] IQVIA Real World Solutions,Steno Diabetes Center North Denmark
[3] IQVIA Real World Solutions,Department of Endocrinology
[4] Boehringer Ingelheim Danmark A/S,undefined
[5] Aalborg University Hospital,undefined
[6] Aalborg University Hospital,undefined
来源：
Diabetes Therapy | 2021年 / 12卷
关键词：
Cardiovascular outcomes; Cost-effectiveness; Diabetes type 2; Empagliflozin; Liraglutide;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1523 / 1534
页数：11
相关论文
共 50 条
  • [1] The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease
    Ehlers, Lars Holger
    Lamotte, Mark
    Monteiro, Sofia
    Sandgaard, Susanne
    Holmgaard, Pia
    Frary, Evan C.
    Ejskjaer, Niels
    [J]. DIABETES THERAPY, 2021, 12 (05) : 1523 - 1534
  • [2] Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China
    Ramos, Mafalda
    Men, Peng
    Wang, Xu
    Ustyugova, Anastasia
    Lamotte, Mark
    [J]. COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2021, 19 (01)
  • [3] Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China
    Mafalda Ramos
    Peng Men
    Xu Wang
    Anastasia Ustyugova
    Mark Lamotte
    [J]. Cost Effectiveness and Resource Allocation, 19
  • [4] Cost-effectiveness analysis of empagliflozin treatment in people with Type 2 diabetes and established cardiovascular disease in the EMPA-REG OUTCOME trial
    Kansal, A.
    Reifsnider, O. S.
    Proskorovsky, I.
    Zheng, Y.
    Pfarr, E.
    George, J. T.
    Kandaswamy, P.
    Ruffolo, A.
    [J]. DIABETIC MEDICINE, 2019, 36 (11) : 1494 - 1502
  • [5] Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease
    Reifsnider, Odette S.
    Kansal, Anuraag R.
    Gandhi, Pranav K.
    Cragin, Lael
    Brand, Sarah B.
    Pfarr, Egon
    Fahrbach, Kyle
    Ustyugova, Anastasia
    [J]. BMJ OPEN DIABETES RESEARCH & CARE, 2021, 9 (01)
  • [6] Cost-effectiveness of Empagliflozin Compared with Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Greece
    Gourzoulidis, George
    Tzanetakos, Charalampos
    Ioannidis, Ioannis
    Tsimihodimos, Vasilis
    Diogo, Viana
    Karpouzos, George
    Papageorgiou, Giannis
    Kourlaba, Georgia
    [J]. CLINICAL DRUG INVESTIGATION, 2021, 41 (04) : 371 - 380
  • [7] Cost-effectiveness of Empagliflozin Compared with Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Greece
    George Gourzoulidis
    Charalampos Tzanetakos
    Ioannis Ioannidis
    Vasilis Tsimihodimos
    Viana Diogo
    George Karpouzos
    Giannis Papageorgiou
    Georgia Kourlaba
    [J]. Clinical Drug Investigation, 2021, 41 : 371 - 380
  • [8] Cost-effectiveness of second-line empagliflozin versus liraglutide for type 2 diabetes in the United States
    Reifsnider, Odette S.
    Pimple, Pratik
    Brand, Sarah
    Washington, Evelien Bergrath
    Shetty, Sharash
    Desai, Nihar R.
    [J]. DIABETES OBESITY & METABOLISM, 2022, 24 (04): : 652 - 661
  • [9] Cost-effectiveness of empagliflozin compared with liraglutide based on cardiovascular outcome trials in Type II diabetes
    Ramos, Mafalda
    Ustyugova, Anastasia
    Hau, Nikco
    Lamotte, Mark
    [J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2020, 9 (11) : 781 - 794
  • [10] COST-EFFECTIVENESS OF LIRAGLUTIDE IN PEOPLE WITH TYPE 2 DIABETES IN THE SLOVAK REPUBLIC
    Ilavska, A.
    Uliciansky, V
    Wrona, W.
    Lacka, J.
    Czech, M.
    [J]. VALUE IN HEALTH, 2010, 13 (07) : A291 - A291
12345